Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 30, 2024
Data Byte

Nine PDUFA dates on FDA’s agenda in September

Decision on Zevra’s arimoclomol follows positive AdCom vote
BioCentury | Jan 24, 2024
Data Byte

Schizophrenia pipeline: two PDUFA dates and a dozen readouts in 2024

A look ahead to the schizophrenia milestones coming this year, and the mechanisms behind them
BioCentury | Apr 25, 2022
Data Byte

Mechanistic diversity in the pipeline for fragile X syndrome

The fragile X pipeline comprises as many drugs targets as drug candidates
BioCentury | Aug 13, 2021
Product Development

Aug. 12 Quick Takes: another hold for Aprea’s eprenetapopt 

Plus Vyne, AlzeCure and Jazz 
BioCentury | Oct 9, 2020
Deals

Oct. 8 Quick Takes: Kronos ready for NASDAQ debut; plus Sensei, TCRyption, Jazz, Pfizer-Opko and Moderna

Kronos raises $250M in NASDAQ IPOLook for shares of Kronos Bio Inc. (NASDAQ:KRON) to begin trading on Friday after the company raised $250 million in an IPO. The listing completes a busy few months
BioCentury | Sep 25, 2020
Emerging Company Profile

XWPharma: timing therapy to biological rhythm

XWPharma to use $40M series C to advance two lead neurology programs
BioCentury | Apr 5, 2019
Clinical News

Jazz planning NDA for narcolepsy therapy JZP-258

Items per page:
1 - 10 of 103